THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA

Objective: Marginal zone lymphoma is a biologically and clinically heterogeneous group of indolent lymphoproliferative diseases, constituting 5-15% of all NHLs (Non-Hodgkin Lymphoma) 1. By the World Health Organization; subgroups as extranodal marginal zone lymphoma (ENMZL, MALT lymphoma, Maltoma),...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Esra TURAN ERKEK, Tuba TAHTALI
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/0e92e784e0fe4f59aaa1759f20bd6b39
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0e92e784e0fe4f59aaa1759f20bd6b39
record_format	dspace
spelling	oai:doaj.org-article:0e92e784e0fe4f59aaa1759f20bd6b392021-11-10T04:36:05ZTHE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA2531-137910.1016/j.htct.2021.10.1038https://doaj.org/article/0e92e784e0fe4f59aaa1759f20bd6b392021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011858https://doaj.org/toc/2531-1379Objective: Marginal zone lymphoma is a biologically and clinically heterogeneous group of indolent lymphoproliferative diseases, constituting 5-15% of all NHLs (Non-Hodgkin Lymphoma) 1. By the World Health Organization; subgroups as extranodal marginal zone lymphoma (ENMZL, MALT lymphoma, Maltoma), nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL) constitute 70%, 20%, 10% of MZL (Marginal Zone Lymphoma) cases, respectively. Methodology: A total of 50 patients with a diagnosis of MZL who applied to our hospital between 2013 and 2021 were included in this retrospective study. All analyzes were performed on SPSS v21. The Kolmogorov-Smirnov test was used for normality control. Data are given as mean ± standard deviation for continuous variables and frequency for categorical variables. Survival times were calculated using the Kaplan Meier method. Cox regression analysis (enter method) was performed to identify important prognostic factors. p<0.05 values were accepted as statistically significant results. Results: The mean age of 50 people in the study group was 62.88 ± 11.50 years and ranged from 34 to 84 years. 50% of the participants were male and 50% were female . The mean follow-up period of the patients was 51.80 ± 27.47 months. It was observed that none of the parameters measured in the study, such as age, gender, body mass index, diabetes, heart disease, thyroid diseases, non-hematological malignancies, chemotherapy, and radiotherapy intake, had an effect on survival. Conclusion: Age at diagnosis should be considered in risk assessment of patients with marginal zone lymphoma. It is thought that the fact that the patients are predominantly in the advanced stage MZL group, and the relatively short follow-up period compared to the indolen lymphoma group, has an effect on the absence of a determining effect of comorbid diseases on mortality. Prognostic markers determined by multicenter and detailed studies are needed to provide a better prediction.Esra TURAN ERKEKTuba TAHTALIElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S43- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Esra TURAN ERKEK Tuba TAHTALI THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
description	Objective: Marginal zone lymphoma is a biologically and clinically heterogeneous group of indolent lymphoproliferative diseases, constituting 5-15% of all NHLs (Non-Hodgkin Lymphoma) 1. By the World Health Organization; subgroups as extranodal marginal zone lymphoma (ENMZL, MALT lymphoma, Maltoma), nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL) constitute 70%, 20%, 10% of MZL (Marginal Zone Lymphoma) cases, respectively. Methodology: A total of 50 patients with a diagnosis of MZL who applied to our hospital between 2013 and 2021 were included in this retrospective study. All analyzes were performed on SPSS v21. The Kolmogorov-Smirnov test was used for normality control. Data are given as mean ± standard deviation for continuous variables and frequency for categorical variables. Survival times were calculated using the Kaplan Meier method. Cox regression analysis (enter method) was performed to identify important prognostic factors. p<0.05 values were accepted as statistically significant results. Results: The mean age of 50 people in the study group was 62.88 ± 11.50 years and ranged from 34 to 84 years. 50% of the participants were male and 50% were female . The mean follow-up period of the patients was 51.80 ± 27.47 months. It was observed that none of the parameters measured in the study, such as age, gender, body mass index, diabetes, heart disease, thyroid diseases, non-hematological malignancies, chemotherapy, and radiotherapy intake, had an effect on survival. Conclusion: Age at diagnosis should be considered in risk assessment of patients with marginal zone lymphoma. It is thought that the fact that the patients are predominantly in the advanced stage MZL group, and the relatively short follow-up period compared to the indolen lymphoma group, has an effect on the absence of a determining effect of comorbid diseases on mortality. Prognostic markers determined by multicenter and detailed studies are needed to provide a better prediction.
format	article
author	Esra TURAN ERKEK Tuba TAHTALI
author_facet	Esra TURAN ERKEK Tuba TAHTALI
author_sort	Esra TURAN ERKEK
title	THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
title_short	THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
title_full	THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
title_fullStr	THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
title_full_unstemmed	THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
title_sort	effect of comorbidity and body mass index on survival in patients with marginal zone lymphoma
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/0e92e784e0fe4f59aaa1759f20bd6b39
work_keys_str_mv	AT esraturanerkek theeffectofcomorbidityandbodymassindexonsurvivalinpatientswithmarginalzonelymphoma AT tubatahtali theeffectofcomorbidityandbodymassindexonsurvivalinpatientswithmarginalzonelymphoma AT esraturanerkek effectofcomorbidityandbodymassindexonsurvivalinpatientswithmarginalzonelymphoma AT tubatahtali effectofcomorbidityandbodymassindexonsurvivalinpatientswithmarginalzonelymphoma
_version_	1718440531442270208

THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA

Ejemplares similares